Is TDAC's revenue cost management improving recently?

**Translational's revenue cost management appears to be stable rather than improving recently.** Here's the analysis to support this conclusion: 1. **No Recent Improvement in Revenue Growth**: The data shows that the Cost of Sales for Translational has not experienced any YoY growth, remaining at $10.17. This indicates a lack of improvement in revenue cost management, as the company is not able to increase revenue to offset cost changes. 2. **Static Revenue and Cost Data**: The absence of specific revenue and cost data beyond the fiscal date and last price suggests that there may not be enough information to assess recent changes in revenue cost management. 3. **Focus on Other Areas**: Companies like Knife River Corporation and ImmuCell Corporation are focusing on generating shareholder value, increasing free cash flow, and reducing debt, which indicates a proactive approach to financial management. In contrast, Translational's financial management approach is not currently available or does not appear to be prioritized in the available data.